HIF1A and neoplasm: The designed MOF NPs, PCN-ACF-CpG@HA, could target tumor cells via HA, block the HIF-1 mediated survival and metastasis signaling of ACF and boost strong host anticancer immune responses to eliminate residual cancer cells with CpG, thus enhancing the therapeutic effects of PDT.